Skip to main content
SpringerLink
Log in

Synthesis and evaluation of cyclic diamino benzamide based D3 receptor ligands

  • Original Research
  • Published:
Medicinal Chemistry Research Aims and scope Submit manuscript

Abstract

Dopamine (1) is a key neurotransmitter whose impact on pharmacological processes is mediated by a family of dopamine receptors designated D1, D2, D3, D4, and D5. Various diseases and conditions such as schizophrenia, drug abuse, depression, restless leg syndrome, Parkinson’s disease (PD), and inflammatory diseases have been linked to aberrant D3 activity. Herein, we report a series of novel D3 ligands with improved solubility over our previous lead compound, MC25-41 (2).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Scheme. 1
Fig. 2
Scheme. 2
Scheme. 3

Similar content being viewed by others

References

  1. Fahn S. The history of dopamine and levodopa in the treatment of Parkinson’s disease. Mov Disord. 2008;23:S497–508. https://doi.org/10.1002/mds.22028.

    Article  PubMed  Google Scholar 

  2. Björklund A, Dunnett SB. Fifty years of dopamine research. Trends Neurosci. 2007;30:185–7. https://doi.org/10.1016/j.tins.2007.03.004.

    Article  CAS  PubMed  Google Scholar 

  3. Benes FM. Carlsson and the discovery of dopamine. Trends Pharmacol Sci. 2001;22:46–47. https://doi.org/10.1016/S0165-6147(00)01607-2.

    Article  CAS  PubMed  Google Scholar 

  4. Roeper J. Dissecting the diversity of midbrain dopamine neurons. Trends Neurosci. 2013;36:336–42.

    Article  CAS  Google Scholar 

  5. Jaber M, Robinson SW, Missale C, Caron MG. Dopamine receptors and brain function. Neuropharm. 1996;35:1503–19. https://doi.org/10.1016/s0028-3908(96)00100-1.

    Article  CAS  Google Scholar 

  6. Kiss B, Laszlovszky I, Krámos B, Visegrády A, Bobok A, Lévay G, et al. Neuronal dopamine D3 receptors: translational implications for preclinical research and CNS disorders. Biomolecules. 2021;11:104 https://doi.org/10.3390/biom11010104.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Bono F, Mutti V, Fiorentini C, Missale C. Dopamine D3 receptor heteromerization: implications for neuroplasticity and neuroprotection. Biomolecules. 2020a;10:1016 https://doi.org/10.3390/biom10071016.

    Article  CAS  PubMed Central  Google Scholar 

  8. Yang P, Perlmutter JS, Benzinger TLS, Morris JC, Xu J. Dopamine D3 receptor: a neglected participant in Parkinson Disease pathogenesis and treatment? Ageing Res Rev. 2020b;57:100994 https://doi.org/10.1016/j.arr.2019.100994.

    Article  CAS  PubMed  Google Scholar 

  9. Feng Y, Lu Y. Immunomodulatory effects of dopamine in inflammatory diseases. Front Immunol. 2021;12:663102–0. https://doi.org/10.3389/fimmu.2021.663102.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Chen PJ, Taylor M, Griffin SA, Amani A, Hayatshahi H, Korzekwa K, et al. Design, synthesis, and evaluation of N-(4-(4-phenyl piperazin-1-yl)butyl)-4-(thiophen-3-yl)benzamides as selective dopamine D3 receptor ligands. Bioorg Med Chem Lett 2019;29:2690–4. https://doi.org/10.1016/j.bmcl.2019.07.020.

    Article  CAS  PubMed  Google Scholar 

  11. Powell GL, Namba MD, Vannan A, Bonadonna JP, Carlson A, Mendoza R, et al. The long-acting D3 partial agonist MC-25-41 attenuates motivation for cocaine in Sprague-Dawley rats. Biomolecules. 2020;10:1076 https://doi.org/10.3390/biom10071076.

    Article  CAS  PubMed Central  Google Scholar 

  12. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995;12:413–20. https://doi.org/10.1023/a:1016212804288.

    Article  CAS  PubMed  Google Scholar 

  13. Pajouhesh H, Lenz GR. Medicinal chemical properties of successful central nervous system drugs. NeuroRx. 2005;2:541–53. https://doi.org/10.1602/neurorx.2.4.541.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Oh T, Daadi, ES, Kim J, Daadi, EW, Chen PJ, Roy-Choudhury G, et al., Dopamine D3 receptor ligand suppresses the expression of levodopa-induced dyskinesia in nonhuman primate model of Parkinson’s Disease. Exp Neurol. https://doi.org/10.1101/2021.08.10.455884.

  15. Blass BE, Basic principles of drug discovery and development 2nd edn, Academic Press: Cambridge Massachusetts (Printed in the United States) 2021. 5, 257–303, https://doi.org/10.1016/B978-0-12-817214-8.00005-1.

  16. O’neill, DJ, Eddine S, Kang, SWA, Andrew Brearley, A, Jonathan Bentley J, Purrole m TORC inhibitors and uses thereof, WO2018089493, 2018.

  17. Lee B, Taylor M, Griffin SA, McInnis T, Sumien N, Mach RH, et al. Evaluation of substituted N-phenylpiperazine analogs as D3 vs. D2 dopamine receptor subtype selective ligands. Molecules. 2021;26:3182 https://doi.org/10.3390/molecules26113182.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The research reported in this publication was supported by the National Institute on Drug Abuse (NIDA)/National Institutes of Health (NIH) under award numbers DA029840-06A1 and DA023957.

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Sciences, Temple University School of Pharmacy, 3307 North Broad Street, Philadelphia, PA, 194140, USA

    Benjamin E. Blass, Peng-Jen Chen, John C. Gordon & Robert R. Luedtke

  2. Department of Pharmacology and Neuroscience, Center, University of North Texas Health Science, 3500 Camp Bowie Blvd, Fort Worth, TX, 76107, USA

    Michelle Taylor & Suzy A. Griffin

Authors
  1. Benjamin E. Blass
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peng-Jen Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michelle Taylor
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Suzy A. Griffin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. John C. Gordon
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Robert R. Luedtke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Benjamin E. Blass.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Blass, B.E., Chen, PJ., Taylor, M. et al. Synthesis and evaluation of cyclic diamino benzamide based D3 receptor ligands. Med Chem Res 31, 446–461 (2022). https://doi.org/10.1007/s00044-021-02845-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00044-021-02845-z

Keywords

Search

Navigation